Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History KPTI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics KPTI

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Karyopharm Therapeutics Inc

KPTI
Current price
4.23 USD -0.16 USD (-3.64%)
Last closed 4.39 USD
ISIN US48576U2050
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 37 929 160 USD
Yield for 12 month -64.31 %
1Y
3Y
5Y
10Y
15Y
KPTI
21.11.2021 - 28.11.2021

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. Address: 85 Wells Avenue, Newton, MA, United States, 02459-3298

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

29.25 USD

P/E Ratio

Dividend Yield

Financials KPTI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures KPTI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+145 237 000 USD

Last Year

+146 033 000 USD

Current Quarter

+30 015 000 USD

Last Quarter

+30 542 000 USD

Current Year

+139 230 000 USD

Last Year

+141 091 000 USD

Current Quarter

+28 714 000 USD

Last Quarter

+29 211 000 USD
EBITDA -118 607 000 USD
Operating Margin TTM -110.80 %
Price to Earnings
Return On Assets TTM -44.76 %
PEG Ratio -0.15
Return On Equity TTM -891.05 %
Wall Street Target Price 29.25 USD
Revenue TTM 142 126 000 USD
Book Value -24.03 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -9.40 %
Dividend Yield
Gross Profit TTM 137 536 000 USD
Earnings per share -11.87 USD
Diluted Eps TTM -11.87 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -43.99 %

Stock Valuation KPTI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.10
Price Sales TTM 0.27
Enterprise Value EBITDA -1.85
Price Book MRQ 12.05

Technical Indicators KPTI

For 52 Weeks

3.51 USD 16.95 USD
50 Day MA 5.08 USD
Shares Short Prior Month 2 073 899
200 Day MA 8.66 USD
Short Ratio 23.36
Shares Short 2 022 280
Short Percent 23.59 %